Evaluation Study
Journal Article
Add like
Add dislike
Add to saved papers

Ultraviolet-B treatment for cutaneous lichen planus: our experience with 50 patients.

BACKGROUND: Previous small reports suggested the role of ultraviolet (UV)-B in the management of cutaneous lichen planus.

OBJECTIVE: To summarize our experience with UVB in a relatively large study group looking specifically into predictive factors for complete response and the long-term relapse rates.

METHODS: A retrospective analysis of 50 patients with generalized cutaneous lichen planus, treated by broad or narrow band UVB.

RESULTS: Seven and 43 patients were treated by broad and narrow band UVB, respectively. Complete response was achieved in 70% and 85% of those were still in remission after a median of 34.7 months. The complete response rate and the need for higher cumulative exposure doses were not influenced by sex, age, skin type, presence of additional diseases, failure of previous treatment or disease duration.

LIMITATIONS: This is a retrospective non-randomized analysis of a usually self-limiting disease.

CONCLUSION: UVB is a safe and efficient treatment option for generalized cutaneous lichen planus.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app